What is Hummingbird Bioscience?
Founded in 2015 and headquartered in Texas, Hummingbird Bioscience operates at the intersection of systems biology and drug discovery. The company specializes in the development of novel therapeutics that target complex disease pathways, aiming to improve patient outcomes where traditional pharmacological approaches have failed. By leveraging a data-driven, precision-medicine framework, Hummingbird Bioscience has established itself as a critical player in the global biotech ecosystem, attracting high-profile institutional backing to support its robust pipeline of clinical-stage assets.
How much funding has Hummingbird Bioscience raised?
Hummingbird Bioscience has raised a total of $275M across 3 funding rounds:
Series B
$25M
Series C
$125M
Series C
$125M
Series B (2020): $25M with participation from Delian Capital, SK Holdings Co., Ltd., SEED Capital, GNTech Venture Capital, Mirae Asset Global Investments, and heritascapital.com
Series C (2021): $125M led by Frazier Healthcare Partners, Novo Holdings, Amgen Ventures, EDBI, and Octagon Capital
Series C (2025): $125M supported by Novo Holdings, Polaris Partners, Droia, Ally Bridge Group, Octagon Capital Group, Pureos Bioventures, Morningside Venture Capital, Amgen, Edbi, Frazier Healthcare Partners, Affinity Asset Advisors, Altrium, and Singapore Economic Development Board
Key Investors in Hummingbird Bioscience
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term value creation in the life sciences sector.
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing deep operational expertise.
Droia
Droia Ventures is a specialist investor dedicated to making a tangible impact on patient lives by investing in the most promising life science companies.
What's next for Hummingbird Bioscience?
With this latest round of financing, Hummingbird Bioscience is well-positioned to scale its clinical operations and expand its research capabilities. The strategic focus will likely shift toward advancing lead candidates through late-stage trials and strengthening its intellectual property portfolio. As the company continues to navigate the complexities of drug development, the support from its diverse syndicate of global investors provides the necessary runway to transform its innovative scientific discoveries into viable, market-ready medical solutions that address significant unmet clinical needs.
See full Hummingbird Bioscience company page
